Leptomeningeal carcinomatosis

Area of Science:

• Neuro-oncology
• Neurology
• Oncology

Background:

• Leptomeningeal carcinomatosis (LC) affects ~5% of cancer patients, with increasing incidence due to improved diagnostics and patient longevity.
• Commonly associated with breast, lung, and melanoma cancers, LC arises from tumor cell spread via hematogenous or direct extension.
• Tumor cells disseminate through cerebrospinal fluid (CSF), causing neurological deficits via nerve injury, direct invasion, vascular compromise, or CSF flow obstruction.

Purpose of the Study:

• To review the diagnosis, clinical presentation, and management of leptomeningeal carcinomatosis.
• To highlight the critical need for early diagnosis and therapeutic intervention in preserving neurological function.
• To discuss current treatment outcomes, prognostic factors, and the challenges posed by treatment-related toxicities.

Main Methods:

• Diagnosis primarily relies on lumbar puncture with CSF cytology, though false negatives occur (~10%).
• Neuroimaging studies can reveal subarachnoid masses, meningeal enhancement, or hydrocephalus.
• Evaluation of clinical presentation, neurological deficits, and systemic tumor status is essential.

Main Results:

• Untreated LC has a median survival of 4-6 weeks, with death from progressive neurological dysfunction.
• Combined radiation therapy and intrathecal chemotherapy improve median survival to 3-6 months.
• Favorable prognostic factors include good performance status, absence of fixed deficits, normal CSF flow, and controlled systemic disease.

Conclusions:

• Early diagnosis and aggressive therapy are crucial for managing leptomeningeal carcinomatosis, despite limited survival benefits and significant toxicities.
• Treatment-related toxicities, such as necrotizing leukoencephalopathy, complicate management.
• Further research into the mechanisms of neurotoxicity from antineoplastic agents is needed to improve patient outcomes.